Monte Rosa Therapeutics Inc Stock

$7.74

8.73% yesterday

Nasdaq, Nov 15, 10:00 pm CET

ISIN

US61225M1027

Symbol

GLUE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Monte Rosa Therapeutics Inc Stock price

$7.74

-13.44 63.46% 5Y

Nasdaq, Closing price Fri, Nov 15 2024

-0.74 8.73%

ISIN

US61225M1027

Symbol

GLUE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$475.52m
Enterprise Value	$277.03m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	18.49
P/S ratio (TTM) P/S ratio	31.74
P/B ratio (TTM) P/B ratio	2.31
Revenue (TTM) Revenue	$14.98m
EBIT (operating result TTM) EBIT	$-128.98m
Free Cash Flow (TTM) Free Cash Flow	$-62.79m
Cash position	$242.19m
EPS (TTM) EPS	$-1.83
P/E forward	negative
P/S forward	7.86
EV/Sales forward	4.86
Short interest	23.35%

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Get Started for Free Today

Monte Rosa Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

7x Buy

100%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Monte Rosa Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	15 15	- 100%
- Direct Costs	7.91 7.91	12% 12% 53%
Gross Profit	7.07 7.07	200% 200% 47%
- Selling and Administrative Expenses	26 26	5% 5% 175%
- Research and Development Expense	102 102	0% 0% 680%
EBITDA	-121 -121	10% 10% -808%
- Depreciation and Amortization	7.91 7.91	12% 12% 53%
EBIT (Operating Income) EBIT	-129 -129	8% 8% -861%
Net Profit	-119 -119	10% 10% -797%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Monte Rosa Therapeutics Inc Stock News

Positive

Investopedia

●

18 days ago

This Biotech Stock Has Doubled Its Value Today—Here's Why

Shares of Monte Rosa Therapeutics (GLUE) more than doubled Monday after the biotechnology company struck an exclusive development and commercialization license agreement with Novartis (NVS) for its treatments for immune system diseases that could be worth more than $2 billion.

Positive

Investors Business Daily

●

18 days ago

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis

Monte Rosa Therapeutics shares doubled Monday on a deal with Novartis to develop treatments for immune system conditions.

Neutral

GlobeNewsWire

●

19 days ago

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is eligible to receive milestone payments, U.S. profit and loss share, and tiered royalties on ex-U.S. net sales BOSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), ...

More Monte Rosa Therapeutics Inc News

Company Profile

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Head office	United States
CEO	Markus Warmuth
Employees	133
Founded	2019
Website	www.monterosatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now